Biogen Asks For Yet More Patience As Leqembi Sales Begin Slow Ascent
Skyclarys From Reata A More Immediate Revenue Source
CEO Chris Viehbacher outlined progress Biogen made in the third quarter, including full approval for the Eisai-partnered Alzheimer’s drug Leqembi, but recent wins will take time to make up for long-term revenue declines.
You may also be interested in...
Sage and Biogen set a $15,900 list price for Zurzuvae, the 14-day postpartum depression drug approved in the US in August, and expect broad access but formulary discussions will continue into 2024.
The first results for subcutaneous lecanemab in early Alzheimer’s disease show better amyloid clearance with slightly higher ARIA rates than the I.V. version. Eisai also presented Phase III Clarity AD updates and initial long-term extension data.
After showing an impressive 60% reduction in tau levels in the brain, Biogen’s Phase I study of BIIB080 has now demonstrated early signs of an impact on cognition and daily living for Alzheimer’s patients.